Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Vaxcyte (NASDAQ:PCVX) and maintained a $95 price target on the stock.

April 10, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Vaxcyte and maintained a $95 price target.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Joseph Stringer suggests a strong bullish sentiment towards Vaxcyte. This could positively influence investor perception and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100